{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:54:30Z","timestamp":1778561670044,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.mehy.2021.110576","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T10:25:52Z","timestamp":1616495152000},"page":"110576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Dual engineered gold nanoparticle based synergistic prophylaxis delivery system for HIV\/AIDS"],"prefix":"10.1016","volume":"150","author":[{"given":"Purnima","family":"Rawat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharad","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mehy.2021.110576_b0005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian human immunodeficiency virus infection","volume":"6","author":"Baba","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.mehy.2021.110576_b0010","unstructured":"Global AIDS, Response Progress Reporting, 2014."},{"key":"10.1016\/j.mehy.2021.110576_b0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.addr.2016.02.010","article-title":"Role of nanotechnology in HIV\/AIDS vaccine development","volume":"103","author":"Liu","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.mehy.2021.110576_b0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM199808063390612","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"339","author":"Michaels","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110576_b0025","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Eng J Med"},{"key":"10.1016\/j.mehy.2021.110576_b0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/313598","article-title":"Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response","volume":"30","author":"Giudici","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.mehy.2021.110576_b0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mehy.2021.110576_b0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/427192","article-title":"Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy","volume":"191","author":"Harrigan","year":"2005","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.mehy.2021.110576_b0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/17425247.3.5.613","article-title":"Nanoparticulate drug carriers for delivery of HIV\/ AIDS therapy to viral reservoir sites","volume":"3","author":"Vyas","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.mehy.2021.110576_b0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/17469600.1.1.49","article-title":"Nanotechnology-based delivery systems in HIV\/AIDS therapy","volume":"1","author":"Shahiwala","year":"2007","journal-title":"Future HIV Ther"},{"issue":"6679 Suppl.","key":"10.1016\/j.mehy.2021.110576_b0055","first-page":"5","article-title":"Drug delivery and targeting","volume":"392","author":"Langer","year":"1998","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mehy.2021.110576_b0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","article-title":"Nanoparticulate systems for brain delivery of drugs","volume":"47","author":"Kreuter","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"4-5","key":"10.1016\/j.mehy.2021.110576_b0065","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.addr.2009.11.017","article-title":"Nanotechnology-based systems for the treatment and prevention of HIV\/AIDS","volume":"62","author":"das Neves","year":"2010","journal-title":"Adv Drug Delivery Rev"},{"key":"10.1016\/j.mehy.2021.110576_b0070","series-title":"HIV and the pathogenesis of AIDS","author":"Levy","year":"2007"},{"issue":"26","key":"10.1016\/j.mehy.2021.110576_b0075","doi-asserted-by":"crossref","first-page":"12799","DOI":"10.1021\/la702151q","article-title":"Aggregation-resistant water-soluble gold nanoparticles","volume":"23","author":"Rouhana","year":"2007","journal-title":"Langmuir"},{"key":"10.1016\/j.mehy.2021.110576_b0080","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3762\/bjoc.13.100","article-title":"Glyco-gold nanoparticles: synthesis and applications","volume":"13","author":"Compostella","year":"2017","journal-title":"Beilstein J Org Chem"},{"key":"10.1016\/j.mehy.2021.110576_b0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.addr.2015.11.015","article-title":"Polysaccharide-based Nanoparticles for Theranostic Nanomedicine","volume":"99","author":"Swierczewska","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.mehy.2021.110576_b0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/fvl-2015-0010","article-title":"Gold nanoparticles and their applications in biomedicine","volume":"11","author":"Versiani","year":"2016","journal-title":"Futur Virol"},{"key":"10.1016\/j.mehy.2021.110576_b0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/138955708783498078","article-title":"Recent advances in inorganic nanoparticle-based drug delivery systems","volume":"8","author":"Tsuchida","year":"2008","journal-title":"Min Rev Med Chem"},{"issue":"3","key":"10.1016\/j.mehy.2021.110576_b0100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13404-017-0213-0","article-title":"Engineering of pectin-reduced gold nanoparticles for targeted delivery of an antiviral drug to macrophages: in vitro and in vivo assessment","volume":"50","author":"Borker","year":"2017","journal-title":"Gold Bull"},{"key":"10.1016\/j.mehy.2021.110576_b0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/1040841X.2013.879849","article-title":"Metal nanoparticles: The protective nanoshield against virus infection","volume":"42","author":"Rai","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.mehy.2021.110576_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sajb.2013.01.003","article-title":"Synthesis of silver nanoparticles using the seaweed Codium capitatum PC Silva (Chlorophyceae)","volume":"86","author":"Kannan","year":"2013","journal-title":"S Afr J Bot"},{"issue":"4","key":"10.1016\/j.mehy.2021.110576_b0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00003088-199936040-00004","article-title":"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection","volume":"36","author":"Barry","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mehy.2021.110576_b0120","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2174\/1381612053764869","article-title":"Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome","volume":"11","author":"Barbaro","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2021.110576_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-8454-3-1","article-title":"The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses","volume":"3","author":"Anthonypillai","year":"2006","journal-title":"Cerebrospinal Fluid Res"},{"key":"10.1016\/j.mehy.2021.110576_b0130","first-page":"189","article-title":"Pharmacokinetics and bioavailability of zidovudine in humans","volume":"85","author":"Blum","year":"1988","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.mehy.2021.110576_b0135","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/clpt.1990.86","article-title":"Pharmacokinetics of 2\u2032, 3\u2032-dideoxyadenosine and 2\u2032, 3\u2032-dideoxyinosine in patients with severe human immunodeficiency virus infection","volume":"47","author":"Hartman","year":"1990","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mehy.2021.110576_b0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/106002809202600511","article-title":"Didanosine","volume":"26","author":"Shelton","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.mehy.2021.110576_b0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0923-2516(07)80025-2","article-title":"Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles","volume":"145","author":"Bender","year":"1994","journal-title":"Res Virol"},{"issue":"6","key":"10.1016\/j.mehy.2021.110576_b0150","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/AAC.40.6.1467","article-title":"Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes\/macrophages in vitro","volume":"40","author":"Bender","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.mehy.2021.110576_b0155","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s11095-006-9101-7","article-title":"Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV\/AIDS","volume":"23","author":"Shah","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.mehy.2021.110576_b0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00126334-200312010-00005","article-title":"Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques","volume":"34","author":"Kinman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.mehy.2021.110576_b0165","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s11095-006-9026-1","article-title":"Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir","volume":"23","author":"Snedecor","year":"2006","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.mehy.2021.110576_b0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0005-2736(01)00432-1","article-title":"Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes","volume":"1558","author":"Gagn\u00e9","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mehy.2021.110576_b0175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/156720106776359230","article-title":"A review of nanocarrier-based CNS delivery systems","volume":"3","author":"Tiwari","year":"2006","journal-title":"Curr Drug Deliv"},{"issue":"1-3","key":"10.1016\/j.mehy.2021.110576_b0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(99)00017-4","article-title":"Investigation of distribution, transport and uptake of anti- HIV drugs to the central nervous system","volume":"39","author":"Sawchuk","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"issue":"33","key":"10.1016\/j.mehy.2021.110576_b0185","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.biomaterials.2008.08.004","article-title":"TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs","volume":"29","author":"Rao","year":"2008","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.mehy.2021.110576_b0190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0196-0644(94)70181-4","article-title":"HIV: virology and mechanisms of disease","volume":"24","author":"King","year":"1994","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.mehy.2021.110576_b0195","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mehy.2021.110576_b0200","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/IJN.S165289","article-title":"Chitosan gold nanoparticles induce cell death in HeLa and MCF-7 cells through reactive oxygen species production","volume":"13","author":"Mart\u00ednez-Torres","year":"2018","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.mehy.2021.110576_b0205","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/v11121111","article-title":"Virucidal Activity of Gold Nanoparticles Synthesized by Green Chemistry Using Garlic Extract","volume":"11","author":"Mayra","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.mehy.2021.110576_b0210","doi-asserted-by":"crossref","first-page":"22817","DOI":"10.1039\/C4RA01428F","article-title":"Synthesis of carbohydrate polymer encrusted gold nanoparticles using bacterial exopolysaccharide: a novel and greener approach","volume":"4","author":"Ganesan","year":"2014","journal-title":"RSC Adv"},{"key":"10.1016\/j.mehy.2021.110576_b0215","article-title":"Nano-based drug delivery system: a smart alternative towards eradication of viral sanctuaries in management of Neuro AIDS. Drug Delivery and Translational","author":"Aggarwal","year":"2021","journal-title":"Research"},{"key":"10.1016\/j.mehy.2021.110576_b0220","doi-asserted-by":"crossref","first-page":"102974","DOI":"10.1016\/j.arabjc.2020.102974","article-title":"Green synthesis and characterization of silver-entecavir nanoparticles with stability determination","volume":"14","author":"Muhammad Shoaib","year":"2021","journal-title":"Arabian J Chem"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:24:10Z","timestamp":1759692250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":44,"alternative-id":["S0306987721000943"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110576","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual engineered gold nanoparticle based synergistic prophylaxis delivery system for HIV\/AIDS","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110576"}}